戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 sses the catabolic events that are caused by osteoclastic bone resorption.
2 stic bone formation and indirectly regulates osteoclastic bone resorption.
3  together have established that TSH inhibits osteoclastic bone resorption.
4  ovariectomy-induced bone loss by inhibiting osteoclastic bone resorption.
5 r of NF-kappaB ligand (RANKL), which induces osteoclastic bone resorption.
6 FK) is, in contrast, a negative regulator of osteoclastic bone resorption.
7 ctor kappaB ligand, an essential mediator of osteoclastic bone resorption.
8 ance between osteoblastic bone formation and osteoclastic bone resorption.
9 s from inflammatory reactions that stimulate osteoclastic bone resorption.
10 xpression of lysosomal enzymes essential for osteoclastic bone resorption.
11 d by osteoblasts and seems to be involved in osteoclastic bone resorption.
12 ance between osteoblastic bone formation and osteoclastic bone resorption.
13 ys its so far uncharacterized action against osteoclastic bone resorption.
14 nhanced expression of cytokines that promote osteoclastic bone resorption.
15 hosphonates and their activity in inhibiting osteoclastic bone resorption.
16 L-6), an inflammatory cytokine implicated in osteoclastic bone resorption.
17 which mediates the subsequent stimulation of osteoclastic bone resorption.
18 nt bone loss because of a marked increase in osteoclastic bone resorption.
19 tastases that are characterized by excessive osteoclastic bone resorption.
20 and metastasize into bone tissue by inducing osteoclastic bone resorption.
21  is the major protease responsible for human osteoclastic bone resorption.
22         Superoxide production contributes to osteoclastic bone resorption.
23 tion and sealing zone formation required for osteoclastic bone resorption.
24 I collagen is necessary for PTH induction of osteoclastic bone resorption.
25  formation of the sealing zone, required for osteoclastic bone resorption.
26 family of diseases characterized by impaired osteoclastic bone resorption.
27 d a rising ambient Ca2+ interact to regulate osteoclastic bone resorption.
28 ast precursors with a subsequent increase in osteoclastic bone resorption.
29 reases in osteoblastic matrix deposition and osteoclastic bone resorption.
30  cathepsin O2 may play a major role in human osteoclastic bone resorption.
31 creases bone mass as the result of defective osteoclastic bone resorption.
32 rparts, HIV-1 transgenic rats undergo severe osteoclastic bone resorption, a consequence of an imbala
33  in osteoblastic bone formation activity nor osteoclastic bone resorption activity in vivo.
34 s a key mechanism by which estrogen prevents osteoclastic bone resorption and bone loss.
35 increased ERFE expression, triggers profound osteoclastic bone resorption and bone loss.
36  and atorvastatin (ATV) are known to inhibit osteoclastic bone resorption and have been proposed to h
37 nflammatory bone loss through stimulation of osteoclastic bone resorption and inhibition of osteoblas
38                   Metabolic acidosis induces osteoclastic bone resorption and inhibits osteoblastic b
39 thermore, PTHrP caused a coupled increase in osteoclastic bone resorption and new bone formation that
40 loma bone disease is caused by uncoupling of osteoclastic bone resorption and osteoblastic bone forma
41 e of tumor implantation profoundly inhibited osteoclastic bone resorption and prevented hypercalcemia
42 -9 signaling, resulting in the inhibition of osteoclastic bone resorption and prostate cancer bone me
43    The bone disease is mediated by increased osteoclastic bone resorption and suppressed bone formati
44  an aminobisphosphonate, is known to inhibit osteoclastic bone resorption and was proposed to have os
45       In most cases, hypercalcemia is due to osteoclastic bone resorption, and agents that inhibit or
46 ase of bone is based on giving inhibitors of osteoclastic bone resorption, and bisphosphonates are th
47 calcium in the milk, a process that involves osteoclastic bone resorption but also osteocytes and per
48 nes during osteoclastogenesis, and prevented osteoclastic bone resorption but did not impair osteobla
49 264.7 cells suggested that the inhibition of osteoclastic bone resorption by these compounds did not
50 DO2) is a heritable bone disease of impaired osteoclastic bone resorption caused by missense mutation
51 es associated with osteocytic osteolysis and osteoclastic bone resorption compared to WT males which
52                                              Osteoclastic bone resorption depends upon the cell's abi
53 oblasts takes advantage of the regulation of osteoclastic bone resorption exerted by osteoblasts.
54                                  Accelerated osteoclastic bone resorption has a central role in the p
55 ncreased recognition of factors that promote osteoclastic bone resorption in cancer patients led us t
56                          The mimetic dampens osteoclastic bone resorption in vitro and in vivo.
57 tives that have potent inhibitory effects on osteoclastic bone resorption in vitro and that prevent o
58 teoblastic activity to match the increase in osteoclastic bone resorption induced by estrogen deficie
59 nd 100 microg/l), reversed the inhibition of osteoclastic bone resorption induced by high extracellul
60                It has been hypothesized that osteoclastic bone resorption is a critical component bef
61                                              Osteoclastic bone resorption is a prominent feature of p
62 position, whereas in modern humans extensive osteoclastic bone resorption is found in the same region
63                                    Increased osteoclastic bone resorption leads to periarticular eros
64 ata suggest that the actions of IFN-gamma on osteoclastic bone resorption may be mediated by its effe
65 remodeling, osteoblastic bone formation, and osteoclastic bone resorption, mediated via the TSH recep
66 nment of the tooth because of the failure of osteoclastic bone resorption on the coronal tooth surfac
67                                  Accelerated osteoclastic bone resorption plays a central role in the
68                                    Increased osteoclastic bone resorption plays a central role in the
69 sive loss of bone mass resulting from excess osteoclastic bone resorption relative to osteoblastic bo
70 itory effect of Pyk2(Y402F), suggesting that osteoclastic bone resorption requires both c-Src kinase
71                                              Osteoclastic bone resorption requires cell-matrix contac
72 arge enough shift in systemic pH to increase osteoclastic bone resorption seems untenable.
73 ortisol inhibits acid-induced, cell-mediated osteoclastic bone resorption through a decrease in osteo
74 he aryl hydrocarbon receptor (Ahr) to induce osteoclastic bone resorption through the activation of c
75 wn to enhance osteoblastogenesis and inhibit osteoclastic bone resorption, thus promoting tissue rege
76 s process of osteoblastic bone formation and osteoclastic bone resorption to maintain normal bone mas
77                                              Osteoclastic bone resorption was more sensitive to the i
78 osteoblastic bone formation and by increased osteoclastic bone resorption, we assessed whether oxidiz
79 lly protected from osteocytic osteolysis and osteoclastic bone resorption when allowed to lactate or
80  ovariectomy-induced bone loss by inhibiting osteoclastic bone resorption, whereas flurbiprofen at si
81 ive phosvitin potently inhibited PTH-induced osteoclastic bone resorption with simultaneous new osteo
82 xamination revealed that ibandronate reduced osteoclastic bone resorption, with increased apoptosis i
83 t can target bone loss mediated by excessive osteoclastic bone resorption without affecting osteoblas